Guidant acquires CardioThoracic in $313 million stock swap
This article was originally published in Clinica
Executive Summary
Guidant is to acquire CardioThoracic Systems (CTS) in a stock swap valued at $313 million. The move ends speculation of a bidding war for the minimally-invasive coronary surgery company and leaves shareholders disappointed that the management of the Cupertino, California-based CTS could only gain a 50c premium per share on its trading price last week of $19.00.